Key result
DPI 201-106 markedly increases LV dP/dtmax independent of beta-stimulation in dogs.
Why the study?
DPI 201-106 is a novel cardiotonic agent with marked positive inotropic activity whose cardiovascular effects and mechanism of action require characterization.
Does DPI 201-106 exert positive inotropic effects in animal models?
Population
Anesthetized and conscious dogs, pithed open-chest cats, cardiomyopathic hamsters, vanadate-treated guinea-pig atria
Comparison
DPI 201-106 administration at various doses versus baseline
Design
Preclinical pharmacological study in animal models
Authors
Loading...
Does not support clinical use of DPI 201-106; leaves open translation of its non-beta-adrenergic inotropy to human heart failure.
Does DPI 201-106 exert positive inotropic effects in animal models?
DPI 201-106 demonstrates marked positive inotropic effects in various animal models through a mechanism independent of beta-adrenergic stimulation or catecholamine release.
Salzmann et al. (1986) studied this question. DPI 201-106 was evaluated on Left ventricular dP/dtmax. DPI 201-106 increased left ventricular dP/dtmax by 34-104% in anesthetized dogs and 22-50% in unanesthetized dogs, exerting positive inotropic effects independent of beta-stimulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: